863454-77-7

Upstream product

• 752242-26-5 methyl 3-hydroxy-5-isopropoxybenzoate 
• 2150-44-9 1-carbomethoxy-3,5-dihydroxybenzene 
• 852520-42-4 methyl 3-[(1-methylethyl)oxy]-5-[(phenylmethyl)oxy]benzoate 
• 852520-53-7 3-benzyloxy-5-isopropoxybenzoic acid 

Downstream Products

• 863454-81-3 methyl 3-fluoro-4-[(3-[(1-methylethyl)oxy]-5-{[(1-methyl-1H-pyrazol-3-yl)amino]carbonyl}phenyl)oxy]benzoate 
• 1310807-46-5 3-{[5-(N'-hydroxycarbamimidoyl)pyrazin-2-yl]oxy}-5-isopropoxy-N-(1-methyl-1H-pyrazol-3-yl)benzamide 
• 1310807-47-6 ethyl 3-(5-{3-isopropoxy-5-[(1-methyl-1H-pyrazol-3-yl)carbamoyl]phenoxy}pyrazin-2-yl)-1,2,4-oxadiazole-5-carboxylate 
• 1310807-56-7 ethyl 5-(5-{3-isopropoxy-5-[(1-methyl-1H-pyrazol-3-yl)carbamoyl]phenoxy}pyridin-2-yl)-1,2,4-oxadiazole-3-carboxylate 
• 1310805-69-6 5-(5-{3-isopropoxy-5-[(1-methyl-1H-pyrazol-3-yl)carbamoyl]phenoxy}pyridin-2-yl)-N-methyl-1,3,4-oxadiazole-2-carboxamide 
• 1310807-57-8 5-{3-isopropoxy-5-[(1-methyl-1H-pyrazol-3-yl)carbamoyl]phenoxy}pyridine-2-carboxylic acid 
• 1310807-59-0 ethyl {2-[(5-{3-isopropoxy-5-[(1-methyl-1H-pyrazol-3-yl)carbamoyl]phenoxy}pyridin-2-yl)carbonyl]hydrazino}(oxo)acetate 
• 1310809-56-3 ethyl 5-(5-{3-isopropoxy-5-[(1-methyl-1H-pyrazol-3-yl)carbamoyl]phenoxy}pyridin-2-yl)-1,3,4-oxadiazole-2-carboxylate 
• 1310807-58-9 3-{[6-(hydrazinocarbonyl)pyridin-3-yl]oxy}-5-isopropoxy-N-(1-methyl-1H-pyrazol-3-yl)benzamide 
• 1310809-41-6 C₂₅H₃₀N₆O₆ 
• 1310807-45-4 3-[(5-cyanopyrazin-2-yl)oxy]-5-isopropoxy-N-(1-methyl-1H-pyrazol-3-yl)benzamide 

Relevant academic research and scientific papers

2 -HETEROCYCLYLOXYBENZOYL AMINO HETEROCYCLYL COMPOUNDS AS MODULATORS OF GLUCOKINASE FOR THE TREATMENT OF TYPE 2 DIABETES

Compounds of formula (I) wherein R1, HET-1 and HET-2 are as described in the specification, and their salts, are activators of glucokinase (GLK) and are thereby useful in the treatment of, for example, type 2 diabetes. Processes for preparing compounds of formula (I) are also described.

HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES

Compounds of formula (I), wherein R1, R4, HET-1 and HET-2 are as described in the specification, and their salts and pro-drugs, are activators of glucokinase (GLK) and are thereby useful in the treatment of, for example, type 2 diabetes. Processes for preparing compounds of formula (I) are also described.